FDA Clears IND for IBI363 in Squamous Non–Small Cell Lung Cancer
Written by
Cancer Network
Published
0
comments
0
min
Developers will now initiate the phase 3 MarsLight-11 trial of IBI363 among patients with immunotherapy-resistant squamous non–small cell lung cancer.